BOURNER, Josephine; VAILLANT, Michel; ABDEL SALAM, Alex Paddy; JASPARD, Marie; FRITZELL, Camille; JACOB, Shevin T; FLETCHER, Tom E; RAMHARTER, Michael; AJAYI, Nnennaya; OKOGBENIN, Sylvanus; ERAMEH, Cyril; GRANT, Donald; SAMUELS, Robert; AYODEJI, Oladele Oluwafemi; SPRECHER, Armand; GONCALVES, Bronner P; EDWARDS, Tansy; OLLIARO, Piero; DUVIGNAUD, Alexandre; FRITZELL, Camille; MALVY, Denis

doi:10.3201/eid3102.240251

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

BOURNER, Josephine

VAILLANT, Michel

ABDEL SALAM, Alex Paddy

Langue

Article de revue

Ce document a été publié dans

Emerging Infectious Diseases. 2025-02-01, vol. 31, n° 2, p. 9-16

Résumé en anglais

The current recommendation for treating Lassa fever with ribavirin is supported only by weak evidence. Given the persistent effects in areas with endemic transmission and epidemic potential, there is an urgent need to reassess ribavirin and investigate other potential therapeutic candidates; however, a robust clinical trial method adapted to Lassa fever epidemiology has not yet been established. We propose an adaptive phase II/III multicenter randomized controlled platform trial that uses a superiority framework with an equal allocation ratio and accounts for challenges selecting the primary end point and estimating the target sample size by using an interim analysis.< Réduire

Mots clés en anglais

Lassa Fever

Clinical Trials

Phase II/III Multicenter Randomized Controlled Platform Trial

Viruses

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche